Navigation Links
An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety
Date:12/17/2010

NEW YORK, Dec. 17, 2010 /PRNewswire-FirstCall/ -- A study published this week by ITG (NYSE: ITG) revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year.  Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.  Over 60% of neurologists in ITG's study cited safety concerns and monitoring as limiting their use of the drug, but most indicated that their prescribing of Gilenya will increase significantly over the course of 2011 as they continue to shift inadequate responders from other MS therapies to the new drug.  Early switching data from ITG's proprietary panel of neurologists indicates that BIIB's Avonex may be the biggest loser of all, as nearly one-third of switches to Gilenya thus far have been from Avonex.

The study titled Event Pulse: Launch of Gilenya shows that Gilenya has been detailed heavily to neurologists since its launch.  Neurologists in the study reported more frequent details on Gilenya in November than any of the other MS therapies.  Study findings reveal that Novartis reps seem to be promoting the drug's unique oral formulation and its efficacy compared to market leaders, especially Biogen Idec's Avonex. Still, results from the study show that Novartis has not been able to completely allay neurologists' concerns about Gilenya's safety. Until resolved, Gilenya will likely be prescribed primarily for patients who have discontinued or have had an inadequate response to other MS therapie
'/>"/>

SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
2. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
10. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
11. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and Company ... ) today announced that they have entered into a ... efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, ... Receptor 2 antiangiogenic cancer medicine. The planned study will ... advanced solid tumors. The Phase I study ...
(Date:5/29/2015)... 2015 Educating the community continues to ... the Advancement of Wound Care (AAWC), which was ... AAWC,s corporate partners, the Association provides medical professionals ... AAWC website at http://aawconline.org/education-for-the-generalist/ . The portal ... links to various CME/CEU educational programs. This education ...
(Date:5/28/2015)... and HOUSTON , May 28, ... (TSX-V: EPI) today reported financial results for the second quarter ... unless specified otherwise, are expressed in Canadian dollars and in ... Summary Results ESSA recorded a net loss ... months ended March 31, 2015 (Q2-2015), compared to a net ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14The Association for the Advancement of Wound Care Educates the Public 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... 2012 Allscripts (NASDAQ: MDRX) today announced that ... ™ to manage the revenue cycle for 39 affiliated providers ... integrated Allscripts Electronic Health Record (EHR) to automate ... the insights they need to deliver superior patient care. ...
... SAN FRANCISCO, Jan. 4, 2012  Practice Fusion, the ... community in the US, announced today that its ... a faster, simpler and more streamlined user experience ... technology flagged more than 7,000 deadly drug interactions ...
Cached Medicine Technology:Mammoth Hospital Selects Allscripts RCM Services 2Mammoth Hospital Selects Allscripts RCM Services 3Mammoth Hospital Selects Allscripts RCM Services 4Mammoth Hospital Selects Allscripts RCM Services 5Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 2Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 3
(Date:5/30/2015)... Il (PRWEB) May 30, 2015 Promising ... Clinical Oncology (ASCO) Annual Meeting 2015 show activity of ... in one case specifically against brain metastases and in ... breast cancer patients. , "I am thrilled to have ... in her early 40s. She didn't have any other ...
(Date:5/30/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 30, 2015 ... safe, and simple procedure to lighten or stop ... risks of hysterectomy. This procedure can reduce or stop ... the lining of the uterus (the part that causes ... , About 10 million women suffer from heavy menstrual ...
(Date:5/30/2015)... One of the pervasive problems plaguing the ... available. Often, the ruralness of a location can severely ... areas feeling the crunch of a strained healthcare system, ... paying high premiums and copays, Online USA Doctors ... via the power of the internet. , ...
(Date:5/30/2015)... 30, 2015 Boston Scientific Corp. ... punitive and compensatory damages to a transvaginal mesh ... complications following implantation of the company’s Pinnacle and ... on May 28th in Delaware Superior Court, the ... after the jury found that the implants were ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 EHO offers ... Web Portal that gives hospices the ability to manage ... Because of this business model, EHO has been able ... pricing to its clients and survive among the giants ... hospice management systems three years ago, it has simplified ...
Breaking Medicine News(10 mins):Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Women's Excellence Now Provides NovaSure Treatment 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4
... Diabetes mellitus is an independent risk factor for cardiovascular ... risk by 2-6 fold relative to nondiabetic subjects and ... mellitus patients will die of an atherosclerotic event. In ... cardiovascular disease, and so the presence of even borderline-high-risk ...
... and his colleagues from Southampton University have found a new ... of two or more genes fuse. The research team is ... common form of childhood leukemia, which is called as Acute ... to develop this genetic test. The treatment is given by ...
... Alzheimer’s disease (AD) is one of the most common forms ... the parts of the brain that control thought, memory, and ... an association between AD risk and several vitamins and have ... that total intake of folate at or above the RDA ...
... been demonstrated that our own experience is important to exhibit ... have been working hard to understand what happens in our ... action. The results of the observation show that the actions ... , ,The research points out that we understand the ...
... and vegetables can pave way for a long and healthy ... out that fruits and vegetables can cause dangerous interactions when ... the activity and toxicity of orally administered drugs. The effect ... ,One of the most studied or well documented of these ...
... approximately one in every 1,000 children and is characterized ... factors have been as causative factors for the disorder. ... the age of 16. There is no satisfactory treatment ... symptoms significantly. , ,The five most common types ...
Cached Medicine News:Health News:Feelings Of Sympathy And Empathy Dictated by Personal Experience 2Health News:Feelings Of Sympathy And Empathy Dictated by Personal Experience 3Health News:Guidelines for treatment of juvenile idiopathic arthritis formulated 2
... The patented ratchet design provides fingertip ... ,The Series I Instrument program offers state-of-the-art ... profile, while maintaining strength and durability. Low ... in tight joint spaces. Series I instruments ...
... A broad selection of procedurally ... capability and allow easy access to ... a variety of approaches.,Loop Handled Graspers ... that holds tissue firmly without tearing ...
... selection of procedurally specific tip configurations ... easy access to all areas of ... approaches.,Loop Handled Graspers feature an "infinite ... firmly without tearing or slipping ...
...
Medicine Products: